1-(4-(4-methylpiperazin-1-yl)phenyl)propan-1-one | 1181984-21-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-(4-methylpiperazin-1-yl)phenyl)propan-1-one
• 英文别名: 1-[4-(4-methylpiperazin-1-yl)phenyl]propan-1-one
• CAS: 1181984-21-3
• 化学式: C₁₄H₂₀N₂O
• 分子量: 232.326
• InChiKey: NLSOZTRVROQIOL-UHFFFAOYSA-N

物化性质

• 沸点：
  378.2±37.0 °C(Predicted)
• 密度：
  1.052±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3,5-difluoroaniline 、 1-(4-(4-methylpiperazin-1-yl)phenyl)propan-1-one 在 三氟甲磺酸 作用下， 以 正丁醇 为溶剂， 反应 24.0h， 以39%的产率得到5,7-difluoro-3-methyl-2-(4-(4-methylpiperazin-1-yl)phenyl)quinolin-4(1H)-one
  参考文献：
  名称：

  Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

  摘要：

  A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified similar to 100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further similar to 90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.

  DOI：

  10.1021/acs.jmedchem.6b01718
• 作为产物：
  描述：

  N-甲基哌嗪 、 4'-氟苯丙酮 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以72%的产率得到1-(4-(4-methylpiperazin-1-yl)phenyl)propan-1-one
  参考文献：
  名称：

  Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis

  摘要：

  A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified similar to 100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further similar to 90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.

  DOI：

  10.1021/acs.jmedchem.6b01718

文献信息

• Ruthenium-Catalyzed Remote Electronic Activation of Aromatic CF Bonds
  作者：Andrew J. A. Watson、Benjamin N. Atkinson、Aoife C. Maxwell、Jonathan M. J. Williams

  DOI：10.1002/adsc.201200879

  日期：2013.3.11

  The tandem isomerization and nucleophilic aromatic substitution of allylic fluoro‐substituted benzylic alcohols is described for the first time. In the presence of the ruthenium complex Ru(PPh3)3(CO)(H)2, 1‐(4‐fluorophenyl)prop‐2‐en‐1‐ol is converted into the corresponding para‐amino ketone or para‐phenolic substituted ketone.

  首次描述了烯丙基氟代苄基醇的串联异构化和亲核芳族取代。在钌络合物Ru（PPh 3）3（CO）（H）2存在下，1-（4-氟苯基）prop-2-en-1-ol被转化为相应的对氨基酮或对酚取代的酮。
• Cysteine Protease inhibitors
  申请人：Nilsson Magnus

  公开号：US20080234260A1

  公开（公告）日：2008-09-25

  A compound of the formula II wherein one of R 1 and R 2 is halo and the other is H or halo; R 3 is C 1 -C 4 straight or branched chain, optionally fluorinated, alkyl; R 4 is H; or R 3 together with R 4 and the adjoining backbone carbon defines: a spiro-C 5 -C 7 cycloalkyl, optionally substituted with 1 to 3 substituents selected from halo, hydroxyl, C 1 -C 4 alkyl or C 1 -C 4 haloalkyl; or optionally bridged with a methylene group; or a C 4 -C 6 saturated heterocycle having a hetero atom selected from O, NRa, S, S(═O) 2 ; where Ra is H, C 1 -C 4 alkyl or CH 3 C(═O); R 5 is independently selected from H or methyl; E is —C(═O)—, —S(═O) m —, —NR 5 S(═O) m —, —NR 5 C(═O)—, —OC(═O)—, R 6 is a stable, optionally substituted, monocyclic or bicyclic, carbocycle or heterocycle; m is independently 0,1 or 2; are inhibitors of cathepsin K and useful in the treatment or prophylaxis of osteoporosis.

  化合物II的公式为其中R1和R2中的一个是卤素，另一个是氢或卤素;R3是C1-C4直链或支链，可选择氟代的烷基;R4是氢;或R3与R4和相邻的骨架碳一起定义:一个螺旋C5-C7环烷基，可选地被1至3个取代基所取代，所述取代基选自卤素、羟基、C1-C4烷基或C1-C4卤代烷基;或者可选地通过亚甲基基桥接;或者是一个C4-C6饱和杂环，其中杂原子选自O、NRa、S、S(═O)2;其中Ra是H、C1-C4烷基或CH3C(═O);R5是独立选择的H或甲基;E是—C(═O)—、—S(═O)m—、—NR5S(═O)m—、—NR5C(═O)—、—OC(═O)—;R6是稳定的、可选地取代的、单环或双环、碳环或杂环;m独立地为0、1或2;是猫hepsin K的抑制剂，用于治疗或预防骨质疏松症。
• EP2049522B1
  申请人：——

  公开号：EP2049522B1

  公开（公告）日：2014-05-14
• US7915300B2
  申请人：——

  公开号：US7915300B2

  公开（公告）日：2011-03-29
• Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of <i>Mycobacterium tuberculosis</i>
  作者：W. David Hong、Peter D. Gibbons、Suet C. Leung、Richard Amewu、Paul A. Stocks、Andrew Stachulski、Pedro Horta、Maria L. S. Cristiano、Alison E. Shone、Darren Moss、Alison Ardrey、Raman Sharma、Ashley J. Warman、Paul T. P. Bedingfield、Nicholas E. Fisher、Ghaith Aljayyoussi、Sally Mead、Maxine Caws、Neil G. Berry、Stephen A. Ward、Giancarlo A. Biagini、Paul M. O’Neill、Gemma L. Nixon

  DOI：10.1021/acs.jmedchem.6b01718

  日期：2017.5.11

  A high-throughput screen (HTS) was undertaken against the respiratory chain dehydrogenase component, NADH:menaquinone oxidoreductase (Ndh) of Mycobacterium tuberculosis (Mtb). The 11000 compounds were selected for the HTS based on the known phenothiazine Ndh inhibitors, trifluoperazine and thioridazine. Combined HTS (11000 compounds) and in-house screening of a limited number of quinolones (50 compounds) identified similar to 100 hits and four distinct chemotypes, the most promising of which contained the quinolone core. Subsequent Mtb screening of the complete in-house quinolone library (350 compounds) identified a further similar to 90 hits across three quinolone subtemplates. Quinolones containing the amine-based side chain were selected as the pharmacophore for further modification, resulting in metabolically stable quinolones effective against multi drug resistant (MDR) Mtb. The lead compound, 42a (MTC420), displays acceptable antituberculosis activity (Mtb IC50 = 525 nM, Mtb Wayne IC50 = 76 nM, and MDR Mtb patient isolates IC50 = 140 nM) and favorable pharmacokinetic and toxicological profiles.